Mark W. Womack

Selexis SA provides research and development services in the field of mammalian cell lines. Its product SUREtechnology Platform improves the way cells are used in the discovery, development and manufacturing of recombinant proteins and drugs. The company was founded by Nicolas Mermod, Igor Edouard Fisch and Peter A. Pfister in 2001 and is headquartered in Plan-les-Ouates, Switzerland.

Selexis SA provides research and development services in the field of mammalian cell lines. Its product SUREtechnology Platform improves the way cells are used in the discovery, development and manufacturing of recombinant proteins and drugs. The company was founded by Nicolas Mermod, Igor Edouard Fisch and Peter A. Pfister in 2001 and is headquartered in Plan-les-Ouates, Switzerland.

Selexis SA provides research and development services in the field of mammalian cell lines. Its product SUREtechnology Platform improves the way cells are used in the discovery, development and manufacturing of recombinant proteins and drugs. The company was founded by Nicolas Mermod, Igor Edouard Fisch and Peter A. Pfister in 2001 and is headquartered in Plan-les-Ouates, Switzerland.

Selexis SA provides research and development services in the field of mammalian cell lines. Its product SUREtechnology Platform improves the way cells are used in the discovery, development and manufacturing of recombinant proteins and drugs. The company was founded by Nicolas Mermod, Igor Edouard Fisch and Peter A. Pfister in 2001 and is headquartered in Plan-les-Ouates, Switzerland.

KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC.